BLA 125521 · Eli Lilly and CO
Taltz
Ixekizumab · Injection · Interleukin-17A Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Aug 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Mar 22, 2016
Approved uses
7
Original approval plus efficacy supplements
Registered trials
67
29 Phase 3, 11 recruiting
FAERS reports
37,285
8,108 serious, 561 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 22, 2026.
TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 ) 1.1 Plaque Psoriasis TALTZ ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis. 1.3 Ankylosing Spondylitis TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Non-radiographic Axial Spondyloarthritis TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
Mechanism: Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 4, 2022 Supplement 23 · Efficacy
- May 29, 2020 Supplement 19 · Efficacy LetterLabel
- Mar 26, 2020 Supplement 20 · Efficacy · priority review LetterLabelPediatric Other
- Aug 23, 2019 Supplement 16 · Efficacy LetterLabel
- May 17, 2018 Supplement 9 · Efficacy LabelLetter
- Dec 1, 2017 Supplement 4 · Efficacy LetterLabel
- Mar 22, 2016 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
1 products under this application
- TALTZ · IXEKIZUMAB 80MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ixekizumab" as an intervention, any sponsor and status, largest first.
- A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01646177 · 1,346 participants · Start Jul 28, 2012 · Primary completion May 22, 2014
Drug: Placebo; 50 mg etanercept and 1 more · For: Psoriasis
Sites: Anaheim, California; Bakersfield, California; Bell Gardens, California · 101 sites in all
- A Phase 3 Study in Participants With Moderate to Severe PsoriasisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01474512 · 1,296 participants · Start Nov 16, 2011 · Primary completion Jun 24, 2014
Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Placebo · For: Psoriasis
Sites: Birmingham, Alabama; Anaheim, California; Bakersfield, California · 104 sites in all
- A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT02513550 · 1,257 participants · Start Aug 2015 · Primary completion Nov 2016
Drug: Ixekizumab; Placebo · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Anaheim, California; Beverly Hills, California · 125 sites in all
- A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01597245 · 1,224 participants · Start May 18, 2012 · Primary completion Mar 25, 2014
Drug: 80 mg ixekizumab Dosing Regimen; 50 mg etanercept and 1 more · For: Psoriasis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 118 sites in all
- A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque PsoriasisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03573323 · 1,027 participants · Start Nov 9, 2018 · Primary completion Jul 15, 2019
Drug: Ixekizumab; Guselkumab and 1 more · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 124 sites in all
- COVID-19 VaccinE Response in Rheumatology PatientsPivotal-lookingCompleted
Jeffrey CurtisAcademic, hospital or other
NCT05080218 · 841 participants · Start Nov 15, 2021 · Primary completion Apr 4, 2024
Drug: Upadacitinib; Abatacept and 6 more · For: Rheumatoid Arthritis; Psoriatic Arthritis; Spondylarthritis
Sites: Birmingham, Alabama; Hoover, Alabama; Phoenix, Arizona · 8 sites in all
- A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial SpondyloarthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03129100 · 773 participants · Start May 9, 2017 · Primary completion May 26, 2020
Drug: Ixekizumab; Placebo · For: Axial Spondyloarthritis
Sites: Phoenix, Arizona; Huntington Beach, California; Palm Desert, California · 127 sites in all
- A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic ArthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03151551 · 566 participants · Start Aug 24, 2017 · Primary completion Nov 15, 2018
Drug: Ixekizumab; Adalimumab · For: Psoriatic Arthritis
Sites: Ciudad Autonoma de Buenos Aire, Argentina; Ciudad de Buenos Aires, Argentina; Quilmes, Argentina · 131 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site pain3,931
- psoriasis3,296
- drug ineffective3,287
- injection site erythema2,214
- injection site reaction1,798
- injection site swelling1,659
- incorrect dose administered1,199
- product dose omission issue962
- pain950
- covid-19923
- arthralgia906
- therapy interrupted845
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 405 |
| 2017 | 2,073 |
| 2018 | 3,763 |
| 2019 | 4,770 |
| 2020 | 3,527 |
| 2021 | 4,001 |
| 2022 | 5,000 |
| 2023 | 4,508 |
| 2024 | 4,451 |
| 2025 | 3,435 |
| 2026 | 1,352 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, et al. · Cochrane Database Syst Rev 2025 · Comparative Study, Network Meta-Analysis
- Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.
Lebwohl M, Blauvelt A, Kartman CE, et al. · JAMA Dermatol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
Merola JF, Mease P, Kivitz A, et al. · Arthritis Rheumatol 2026 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, et al. · Cochrane Database Syst Rev 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.